Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Neurology 1994; 44(11 Suppl 9):S44-51; discussion S51-2Neur

Abstract

Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury.

Authors+Show Affiliations

Section of Physical Medicine and Rehabilitation, University of Manitoba, Winnipeg, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7970010

Citation

Nance, P W., et al. "Efficacy and Safety of Tizanidine in the Treatment of Spasticity in Patients With Spinal Cord Injury. North American Tizanidine Study Group." Neurology, vol. 44, no. 11 Suppl 9, 1994, pp. S44-51; discussion S51-2.
Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44-51; discussion S51-2.
Nance, P. W., Bugaresti, J., Shellenberger, K., Sheremata, W., & Martinez-Arizala, A. (1994). Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology, 44(11 Suppl 9), pp. S44-51; discussion S51-2.
Nance PW, et al. Efficacy and Safety of Tizanidine in the Treatment of Spasticity in Patients With Spinal Cord Injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44-51; discussion S51-2. PubMed PMID: 7970010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. AU - Nance,P W, AU - Bugaresti,J, AU - Shellenberger,K, AU - Sheremata,W, AU - Martinez-Arizala,A, PY - 1994/11/1/pubmed PY - 1994/11/1/medline PY - 1994/11/1/entrez SP - S44-51; discussion S51-2 JF - Neurology JO - Neurology VL - 44 IS - 11 Suppl 9 N2 - Tizanidine, an imidazoline that acts as an agonist at alpha 2-adrenergic receptors, has been shown to be effective in reducing spasticity caused by MS. This multicenter study (14 sites) assessed the efficacy and safety of oral tizanidine in patients who had spinal cord injury of > 12 months' duration. Of the 124 patients admitted to the study, 78 completed it. Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d. Muscle tone, assessed by Ashworth score, was significantly reduced (p = 0.0001) by tizanidine treatment in comparison with placebo. Video motion analysis of the pendulum test showed improvement in the tizanidine-treated patients vs placebo (p = 0.04) and showed a significant correlation with the Ashworth score (p < 0.001). No significant alterations in muscle strength or vital signs were noted in either treatment group. The most common adverse events during tizanidine treatment were somnolence, xerostomia, and fatigue. It was concluded that, overall, tizanidine is effective in reducing spasticity in patients with spinal cord injury. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/7970010/Efficacy_and_safety_of_tizanidine_in_the_treatment_of_spasticity_in_patients_with_spinal_cord_injury__North_American_Tizanidine_Study_Group_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=7970010.ui DB - PRIME DP - Unbound Medicine ER -